StockData
BridgeBio Pharma, Inc. logo

BridgeBio Pharma, Inc. (BBIO) income statement

BBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 3/30
$78.01+1.21 (+1.58%)

Close on Nov 18, 2026Market cap $15.20BP/E –Yield –

BridgeBio Pharma, Inc. income statement

Ratios

Latest available, balances at Sep 30, 2026

Profitability, TTM

Gross margin
94.3%
Operating margin
-38.5%
Net margin
–
Return on equity, FY2025
–

Financial strength

Current ratio
2.09
Debt to equity
–
Debt to assets
–
Cash to current liabilities
156.9%

Valuation

P/E ratio
–
Price to sales
16.07
Price to book
–
Dividend yield
–

See a number that looks wrong?